Yan Chen

Ms. Yan Chen

orcid

Research Focus & Metrics

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DFDai-Long Fang
Dai-Long Fang
YCYan Chen
Yan Chen
BXBei Xu
Bei Xu
KRKe Ren
Ke Ren
Zhiyao HeZhiyao He
Zhiyao He
XSXiangrong Song
Xiangrong Song
Salidroside (Sal) is a potent antitumor drug with high water-solubility. The clinic application of Sal in cancer therapy has been significantly restricted by poor oral absorption and low tumor cell uptake. To solve this problem, lipid-shell and polymer-core nanoparticles (Sal-LPNPs) loaded with Sal were developed by a double emulsification method. The processing parameters including the polymer types, organic phase, PVA types and amount were systemically investigated. The obtained optimal Sal-LPNPs, composed of PLGA-PEG-PLGA triblock copolymers and lipids, had high entrapment efficiency (65%), submicron size (150 nm) and negatively charged surface (−23 mV). DSC analysis demonstrated the successful encapsulation of Sal into LPNPs. The core-shell structure of Sal-LPNPs was verified by TEM. Sal released slowly from the LPNPs without apparent burst release. MTT assay revealed that 4T1 and PANC-1 cancer cell lines were sensitive to Sal treatment. Sal-LPNPs had significantly higher antitumor activities than free Sal in 4T1 and PANC-1 cells. The data indicate that LPNPs are a promising Sal vehicle for anti-cancer therapy and worthy of further investigation.

20 April 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
WBWentao Bo
Wentao Bo
YCYan Chen
Yan Chen
Graphical In this review, we summerized the absorption, distribution, metabolism, excretion of lenvatinib in clinic. The lastest mechanism and potential approches to overcome resistance caused by lenvatinib were supplied.

Verified
Journal Article
Open access
PDF file
YCYan Chen
Yan Chen
XZXue-Lian Zheng
Xue-Lian Zheng
DFDai-Long Fang
Dai-Long Fang
YYYang Yang
Yang Yang
JZJin-Kun Zhang
Jin-Kun Zhang
XSXiangrong Song
Xiangrong Song
Multidrug-resistant breast cancers have limited and ineffective clinical treatment options. This study aimed to develop PLGA nanoparticles containing a synergistic combination of vincristine and verapamil to achieve less toxicity and enhanced efficacy on multidrug-resistant breast cancers. The 1:250 molar ratio of VCR/VRP showed strong synergism with the reversal index of approximately 130 in the multidrug-resistant MCF-7/ADR cells compared to drug-sensitive MCF-7 cells. The lyophilized nanoparticles could get dispersed quickly with the similar size distribution, zeta potential and encapsulation efficiency to the pre-lyophilized nanoparticles suspension, and maintain the synergistic in vitro release ratio of drugs. The co-encapsulated nanoparticle formulation had lower toxicity than free vincristine/verapamil combinations according to the acute-toxicity test. Furthermore, the most effective tumor growth inhibition in the MCF-7/ADR human breast tumor xenograft was observed in the co-delivery nanoparticle formulation group in comparison with saline control, free vincristine, free vincristine/verapamil combinations and single-drug nanoparticle combinations. All the data demonstrated that PLGANPs simultaneously loaded with chemotherapeutic drug and chemosensitizer might be one of the most potential formulations in the treatment of multidrug-resistant breast cancer in clinic.

24 June 2020 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
ZLZhixi Liu
Zhixi Liu
ZLZhi Liao
Zhi Liao
YCYan Chen
Yan Chen
LHLizhu Han
Lizhu Han
QYQinan Yin
Qinan Yin
HXHongtao Xiao
Hongtao Xiao

2 February 2020 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
NLNingxi Li
Ningxi Li
YCYan Chen
Yan Chen
HSHuimin Sun
Huimin Sun
THTingwenli Huang
Tingwenli Huang
TCTianyu Chen
Tianyu Chen
MWMin Wu
Min Wu
Objective. A polymer-based nanoparticle was constructed to target sorafenib delivery to colorectal carcinoma cells and decrease the side effects of the drug. Methods. Sorafenib-loaded nanoparticles (S-NPs) based on PEG-PLGA were prepared using a double emulsion solvent evaporation method. The properties of S-NPs were evaluated and then their effects on the viability of colorectal cancer cells and normal human cells were assessed. The mechanism of S-NP internalization was explored using cellular uptake assays and in vitro fluorescence confocal imaging. Acute toxicity of sorafenib on its own or within S-NPs was assessed in mice. Results. S-NPs showed high drug loading and entrapment efficiencies, they did not cause extensive hemolysis, and they efficiently inhibited growth of colorectal cancer cell lines and human umbilical vein endothelial cells. S-NPs showed lower acute toxicity than the free drug. Conclusion. Loading sorafenib into nanoparticles can enhance its uptake by colorectal cancer cells and decrease its acute toxicity.

1 January 2026 in Theranostics
Verified
Journal Article
Open access
PDF file
RYRui Ye
Rui Ye
YZYupei Zhang
Yupei Zhang
WXWan Xu
Wan Xu
LLLi Lai
Li Lai
ZZZhongwei Zhang
Zhongwei Zhang
SQShugang Qin
Shugang Qin
Developing therapies for complex brain diseases faces significant challenges due to biological complexity and the stringent blood-brain barrier. While nanomedicine holds promise, traditional R&D paradigms suffer from inefficiency. This review introduces an intelligent theranostic paradigm that integrates high-fidelity brain organoid models, high-throughput screening (HTS/HCS), and Artificial Intelligence (AI). In this closed-loop workflow, organoid platforms serve a diagnostic role, generating predictive data on nanomedicine performance. AI then provides therapeutic guidance by processing this data to drive rational drug design, synthesis, and interaction prediction. This AI-driven convergence is poised to significantly accelerate the development of precisely targeted and individualized nanomedicines, offering new hope for breakthroughs in treating brain diseases.